|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 54.60 CNY | +1.13% |
|
-3.50% | +23.81% |
| 07-08 | Gan & Lee Pharmaceuticals' Insulin Aspart Receives Approval in Argentina | CI |
| 05-19 | Gan & Lee Pharmaceuticals Completes First Patient Dosing in GZR102 Trial | MT |
Projected Income Statement: Gan & Lee Pharmaceuticals.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3,362 | 3,612 | - | 2,608 | 3,045 | 4,301 | 5,290 | 6,057 |
| Change | - | 7.44% | - | - | 16.77% | 41.23% | 23% | 14.5% |
| EBITDA 1 | - | - | - | 537.8 | 795.7 | 1,482 | 1,841 | 2,210 |
| Change | - | - | - | - | 47.94% | 86.22% | 24.22% | 20.09% |
| EBIT 1 | 1,453 | 1,699 | - | 315.3 | 631.5 | 1,294 | 1,793 | 2,137 |
| Change | - | 16.93% | - | - | 100.31% | 104.9% | 38.56% | 19.19% |
| Interest Paid | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | 1,445 | 1,696 | - | 306.1 | 630.4 | 1,353 | 1,789 | 2,139 |
| Change | - | 17.33% | - | - | 105.91% | 114.63% | 32.22% | 19.56% |
| Net income 1 | 1,231 | 1,453 | -439.5 | 340.1 | 614.7 | 1,128 | 1,489 | 1,789 |
| Change | - | 18.04% | -130.25% | 177.37% | 80.75% | 83.59% | 31.99% | 20.1% |
| Announcement Date | 14/04/21 | 27/04/22 | 30/03/23 | 24/04/24 | 24/04/25 | - | - | - |
1CNY in Million
Estimates
Forecast Balance Sheet: Gan & Lee Pharmaceuticals.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | -2,439 | -893 | -1,314 | -2,276 | -3,434 |
| Change | - | - | - | - | 63.39% | -47.19% | -73.21% | -50.88% |
| Announcement Date | 14/04/21 | 27/04/22 | 30/03/23 | 24/04/24 | 24/04/25 | - | - | - |
1CNY in Million
Estimates
Cash Flow Forecast: Gan & Lee Pharmaceuticals.
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| CAPEX 1 | 552.7 | 440.8 | 100 | 90 | 130 |
| Change | - | -20.25% | -77.31% | -10% | 44.44% |
| Free Cash Flow (FCF) 1 | - | - | - | - | - |
| Change | - | - | - | - | - |
| Announcement Date | 24/04/24 | 24/04/25 | - | - | - |
1CNY in Million
Estimates
Forecast Financial Ratios: Gan & Lee Pharmaceuticals.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
| EBITDA Margin (%) | - | - | - | 20.62% | 26.13% | 34.45% | 34.79% | 36.49% |
| EBIT Margin (%) | 43.22% | 47.03% | - | 12.09% | 20.74% | 30.09% | 33.89% | 35.28% |
| EBT Margin (%) | 43% | 46.95% | - | 11.74% | 20.7% | 31.46% | 33.82% | 35.31% |
| Net margin (%) | 36.61% | 40.22% | - | 13.04% | 20.18% | 26.24% | 28.15% | 29.53% |
| FCF margin (%) | - | - | - | - | - | - | - | - |
| FCF / Net Income (%) | - | - | - | - | - | - | - | - |
Profitability | ||||||||
| ROA | - | - | - | 3.05% | - | 9% | 10.5% | 11.9% |
| ROE | 17.01% | 15.24% | - | 3.44% | 5.55% | 9.8% | 11.45% | 12.9% |
Financial Health | ||||||||
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Debt / Free cash flow | - | - | - | - | - | - | - | - |
Capital Intensity | ||||||||
| CAPEX / Current Assets (%) | - | - | - | 21.19% | 14.47% | 2.33% | 1.7% | 2.15% |
| CAPEX / EBITDA (%) | - | - | - | 102.77% | 55.4% | 6.75% | 4.89% | 5.88% |
| CAPEX / FCF (%) | - | - | - | - | - | - | - | - |
Items per share | ||||||||
| Cash flow per share 1 | 2.211 | 1.922 | - | 0.1842 | 0.8939 | 1.54 | 1.91 | - |
| Change | - | -13.05% | - | - | 385.29% | 72.28% | 24.03% | - |
| Dividend per Share 1 | - | - | - | 0.2 | 1 | 0.18 | 0.24 | 0.29 |
| Change | - | - | - | - | 400% | -82% | 33.33% | 20.83% |
| Book Value Per Share 1 | 15.92 | 18.11 | - | 18.08 | 18.39 | 19.54 | 22.26 | 23.47 |
| Change | - | 13.75% | - | - | 1.72% | 6.24% | 13.89% | 5.46% |
| EPS 1 | 2.31 | 2.59 | -0.78 | 0.6 | 1.04 | 1.928 | 2.522 | 2.975 |
| Change | - | 12.12% | -130.12% | 176.92% | 73.33% | 85.34% | 30.87% | 17.94% |
| Nbr of stocks (in thousands) | 561,540 | 561,540 | 565,653 | 590,049 | 597,089 | 598,962 | 598,962 | 598,962 |
| Announcement Date | 14/04/21 | 27/04/22 | 30/03/23 | 24/04/24 | 24/04/25 | - | - | - |
1CNY
Estimates
| 2025 * | 2026 * | |
|---|---|---|
| P/E ratio | 28.3x | 21.6x |
| PBR | 2.79x | 2.45x |
| EV / Sales | 7.3x | 5.75x |
| Yield | 0.33% | 0.44% |
More valuation ratios
* Estimated data
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
54.60CNY
Average target price
65.00CNY
Spread / Average Target
+19.05%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 603087 Stock
- Financials Gan & Lee Pharmaceuticals.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition